Please login to the form below

caplacizumab

This page shows the latest caplacizumab news and features for those working in and with pharma, biotech and healthcare.

As France protests, Sanofi takes axe to 670 jobs

dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.

Latest news

Dupixent helps put Sanofi back on growth track

Brandicourt is also hoping for new sales momentum from two new product approvals – checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura
Sanofi gets EU OK for Ablynx flagship drug Cablivi

The EU regulator has cleared Cablivi (caplacizumab) for adults with aTTP, and Sanofi says that the drug is the first in Europe to be approved specifically for the rare blood-clotting
Dupixent bounce-back helps stem diabetes declines at Sanofi

hoping that the 3.9bn takeover of antibody specialist Ablynx and lead rare disease drug caplacizumab will also pay off in the years to come.
Sanofi’s rare blood disorder drug Cablivi set for European approval

The EMA’s Committee for Medicinal Products for Human Use (CHMP) gave its blessing to Cablivi (caplacizumab) at its monthly meeting last week, along with three other rare disease therapies, two
Sanofi poaches Peugeot's finance head

It also made a play for nanobody focused biopharma Ablynx, which it acquired for 3.9bn, along with its lead candidate and orphan drug caplacizumab for rare blood disorder acquired thrombotic

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

bid for Ablynx in December, which the Ablynx Board rejected. Novo Nordisk's particular interest was in lead asset caplacizumab, a Nanobody therapeutic which inhibits von Willebrand factor (vWF) for the ... Acquisition company. 7, 000. Ablynx/Sanofi.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Novo Nordisk target Ablynx reshuffles its board

lead, wholly-owned product, caplacizumab, in addition to advancing our extensive pipeline.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Client Services Director – Medical Education Agency – North West...: Salary TBC

Global Business Development Director – Health Education: excellent commission

Senior Medical Writer: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Medical Writer: Salary TBC

Senior Account Manager: Competitive Salary Offered

Account Director – Health Policy – Global Agency: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Associate Director: £75, 000-90, 000

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Senior Director – Healthcare PR – Global Agency: Salary TBC

Account Manager / Account Director: Competative

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Account Director development role to Business Director, H...: Excellent package

Account Director: Competitive Salary Offered

Account Director, Healthcare Marketing Agency: Salary TBC

Business Director: Competitive Salary Offered

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Director, Medical Education: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...